IMPORTANCE: Patients with colorectal cancer (CRC) are up to 4-fold more likely than individuals without a history of cancer to develop cardiovascular disease. Clinical care guidelines recommend that physicians counsel patients with CRC regarding the association between obesity (defined using body mass index [BMI] calculated as weight in kilograms divided by height in meters squared) and cardiovascular disease risk; however, this recommendation is based on expert opinion. OBJECTIVE: To determine which measures of body composition are associated with major adverse cardiovascular events (MACEs) in patients with CRC. DESIGN, SETTING, AND PARTICIPANTS: Population-based retrospective cohort study of 2839 patients with stage I to III CRC diagnosed between January 2006 and December 2011 at an integrated health care system in North America. EXPOSURES: The primary exposures were BMI and computed tomography-derived body composition measurements (eg, adipose tissue compartments and muscle characteristics) obtained at the diagnosis of CRC. MAIN OUTCOMES AND MEASURES: The primary outcome was time to the first occurrence of MACE after diagnosis of CRC, including myocardial infarction, stroke, and cardiovascular death. RESULTS: In this population-based cohort study of 2839 participants with CRC (1384 men and 1455 women), the average age (SD) was 61.9 (11.5) years (range, 19-80 years). A substantial number of patients were former (1127; 40%) or current smokers (340; 12%), with hypertension (1150; 55%), hyperlipidemia (1389; 49%), and type 2 diabetes (573; 20%). The cumulative incidence of MACE 10 years after diagnosis of CRC was 19.1%. Body mass index was positively correlated with some computed tomography-derived measures of body composition. However, BMI was not associated with MACE; contrasting BMI categories of greater than or equal to 35 vs 18.5 to 24.9, the hazard ratio (HR) was 1.23 (95% CI, 0.85-1.77; P = .50 for trend). Visceral adipose tissue area was associated with MACE; contrasting the highest vs lowest quintile, the HR was 1.54 (95% CI, 1.02-2.31; P = .04 for trend). Subcutaneous adipose tissue area was not associated with MACE; contrasting the highest vs lowest quintile, the HR was 1.15 (95% CI, 0.78-1.69; P = .65 for trend). Muscle mass was not associated with MACE; contrasting the highest vs lowest quintile, the HR was 0.96 (95% CI, 0.57-1.61; P = .92 for trend). Muscle radiodensity was associated with MACE; contrasting the highest (ie, less lipid stored in the muscle) vs lowest quintile, the HR was 0.67 (95% CI, 0.44-1.03; P = .02 for trend). CONCLUSIONS AND RELEVANCE: Visceral adiposity and muscle radiodensity appear to be risk factors for MACE. Body mass index may have limited use for determining cardiovascular risk in this patient population.
IMPORTANCE: Patients with colorectal cancer (CRC) are up to 4-fold more likely than individuals without a history of cancer to develop cardiovascular disease. Clinical care guidelines recommend that physicians counsel patients with CRC regarding the association between obesity (defined using body mass index [BMI] calculated as weight in kilograms divided by height in meters squared) and cardiovascular disease risk; however, this recommendation is based on expert opinion. OBJECTIVE: To determine which measures of body composition are associated with major adverse cardiovascular events (MACEs) in patients with CRC. DESIGN, SETTING, AND PARTICIPANTS: Population-based retrospective cohort study of 2839 patients with stage I to III CRC diagnosed between January 2006 and December 2011 at an integrated health care system in North America. EXPOSURES: The primary exposures were BMI and computed tomography-derived body composition measurements (eg, adipose tissue compartments and muscle characteristics) obtained at the diagnosis of CRC. MAIN OUTCOMES AND MEASURES: The primary outcome was time to the first occurrence of MACE after diagnosis of CRC, including myocardial infarction, stroke, and cardiovascular death. RESULTS: In this population-based cohort study of 2839 participants with CRC (1384 men and 1455 women), the average age (SD) was 61.9 (11.5) years (range, 19-80 years). A substantial number of patients were former (1127; 40%) or current smokers (340; 12%), with hypertension (1150; 55%), hyperlipidemia (1389; 49%), and type 2 diabetes (573; 20%). The cumulative incidence of MACE 10 years after diagnosis of CRC was 19.1%. Body mass index was positively correlated with some computed tomography-derived measures of body composition. However, BMI was not associated with MACE; contrasting BMI categories of greater than or equal to 35 vs 18.5 to 24.9, the hazard ratio (HR) was 1.23 (95% CI, 0.85-1.77; P = .50 for trend). Visceral adipose tissue area was associated with MACE; contrasting the highest vs lowest quintile, the HR was 1.54 (95% CI, 1.02-2.31; P = .04 for trend). Subcutaneous adipose tissue area was not associated with MACE; contrasting the highest vs lowest quintile, the HR was 1.15 (95% CI, 0.78-1.69; P = .65 for trend). Muscle mass was not associated with MACE; contrasting the highest vs lowest quintile, the HR was 0.96 (95% CI, 0.57-1.61; P = .92 for trend). Muscle radiodensity was associated with MACE; contrasting the highest (ie, less lipid stored in the muscle) vs lowest quintile, the HR was 0.67 (95% CI, 0.44-1.03; P = .02 for trend). CONCLUSIONS AND RELEVANCE: Visceral adiposity and muscle radiodensity appear to be risk factors for MACE. Body mass index may have limited use for determining cardiovascular risk in this patient population.
Authors: Elena Birman-Deych; Amy D Waterman; Yan Yan; David S Nilasena; Martha J Radford; Brian F Gage Journal: Med Care Date: 2005-05 Impact factor: 2.983
Authors: Rebecca L Siegel; Kimberly D Miller; Stacey A Fedewa; Dennis J Ahnen; Reinier G S Meester; Afsaneh Barzi; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2017-03-01 Impact factor: 508.702
Authors: N J van Leersum; M L G Janssen-Heijnen; M W J M Wouters; H J T Rutten; J W Coebergh; R A E M Tollenaar; V E P P Lemmens Journal: Int J Cancer Date: 2012-11-05 Impact factor: 7.396
Authors: M C Pouliot; J P Després; S Lemieux; S Moorjani; C Bouchard; A Tremblay; A Nadeau; P J Lupien Journal: Am J Cardiol Date: 1994-03-01 Impact factor: 2.778
Authors: Kelly M Kenzik; Courtney Balentine; Joshua Richman; Meredith Kilgore; Smita Bhatia; Grant R Williams Journal: J Clin Oncol Date: 2018-01-16 Impact factor: 44.544
Authors: Stamatina Iliodromiti; Carlos A Celis-Morales; Donald M Lyall; Jana Anderson; Stuart R Gray; Daniel F Mackay; Scott M Nelson; Paul Welsh; Jill P Pell; Jason M R Gill; Naveed Sattar Journal: Eur Heart J Date: 2018-05-01 Impact factor: 29.983
Authors: Justin C Brown; Bette J Caan; Carla M Prado; Elizabeth M Cespedes Feliciano; Jingjie Xiao; Candyce H Kroenke; Jeffrey A Meyerhardt Journal: J Natl Cancer Inst Date: 2020-04-01 Impact factor: 13.506
Authors: Justin C Brown; Jeffrey A Meyerhardt; Elizabeth M Cespedes Feliciano; En Cheng; Bette J Caan Journal: Clin Nutr Date: 2022-05-27 Impact factor: 7.643
Authors: Perry J Pickhardt; Peter M Graffy; Ryan Zea; Scott J Lee; Jiamin Liu; Veit Sandfort; Ronald M Summers Journal: Lancet Digit Health Date: 2020-03-02
Authors: Ye Won Jeon; Hyung Soon Park; Yousun Ko; Yu Sub Sung; Byoung Yong Shim; Young Jin Suh; Hyun A Kim Journal: Breast Cancer Res Treat Date: 2021-07-20 Impact factor: 4.872
Authors: Kirti Magudia; Christopher P Bridge; Camden P Bay; Ana Babic; Florian J Fintelmann; Fabian M Troschel; Nityanand Miskin; William C Wrobel; Lauren K Brais; Katherine P Andriole; Brian M Wolpin; Michael H Rosenthal Journal: Radiology Date: 2020-11-24 Impact factor: 11.105
Authors: Justin C Brown; Bette J Caan; Elizabeth M Cespedes Feliciano; Jingjie Xiao; Erin Weltzien; Carla M Prado; Candyce H Kroenke; Adrienne Castillo; Marilyn L Kwan; Jeffrey A Meyerhardt Journal: Am J Clin Nutr Date: 2021-06-01 Impact factor: 7.045
Authors: G F P Aleixo; H Yu; Y T Chen; K A Nyrop; R J Louie; A M Deal; S S Shachar; H B Muss; G R Williams Journal: Breast Cancer Res Treat Date: 2021-01-10 Impact factor: 4.872
Authors: Justin C Brown; Michael H Rosenthal; Chao Ma; Sui Zhang; Halla S Nimeiri; Nadine J McCleary; Thomas A Abrams; Matthew B Yurgelun; James M Cleary; Douglas A Rubinson; Deborah Schrag; Andrea J Bullock; Jill Allen; Dan Zuckerman; Emily Chan; Jennifer A Chan; Brian Wolpin; Michael Constantine; Douglas J Weckstein; Meredith A Faggen; Christian A Thomas; Chryssanthi Kournioti; Chen Yuan; Hui Zheng; Bruce W Hollis; Charles S Fuchs; Kimmie Ng; Jeffrey A Meyerhardt Journal: Cancers (Basel) Date: 2020-11-20 Impact factor: 6.639
Authors: E Venturini; G Iannuzzo; A D'Andrea; M Pacileo; L Tarantini; M L Canale; M Gentile; G Vitale; F M Sarullo; R Vastarella; A Di Lorenzo; C Testa; A Parlato; C Vigorito; F Giallauria Journal: J Clin Med Date: 2020-06-10 Impact factor: 4.964